[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antithrombotic-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antithrombotic-therapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,87,115,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100415858","phase-4-dual-antithrombotic-therapy-with-dabigatran-and-ticagrelor-in-patients-with-acs-and-non-valvular-af-undergoing-pci-100415858",false,"NCT04695106","Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI","Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI)","ADONIS-PCI","Inclusion Criteria:\n\n* Male and female patients aged ≥18 years'\n* Patients with new-onset or pre-existing non-valvular AF that have been receiving oral anticoagulant treatment with dabigatran for at least 48 hours or were treatment naïve prior to PCI. AF may be paroxysmal, persistent or permanent, but must not be secondary to a reversible disorder such as MI, pulmonary embolism, recent surgery, pericarditis or thyrotoxicosis unless long-term treatment with an OAC is anticipated.\n* Patients presenting with ACS that had undergone a successful PCI with drug-eluting stent (DES) implantation or plain old balloon angioplasty within the previous 120 hours. ACS may be ST-elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), or unstable angina (UA). Successful treatment with PCI is defined as achievement of \\\u003C30% residual diameter stenosis of the target lesion assessed by visual inspection or quantitative coronary angiography and no in-hospital major adverse cardiac events (AMI or repeat coronary revascularisation of the target lesion). For ACS patients with ST-segment elevation, persistent ST-segment elevation of at least 0.1 mV in at least two contiguous leads or a new left bundle-branch block should be present. For ACS patients without ST-segment elevation, at least two of the following three criteria should be met: (i) ST-segment changes on electrocardiography, indicating ischemia; (ii) a positive test of a biomarker, indicating myocardial necrosis; or (iii) one of several risk factors (age ≥60 years; previous myocardial infarction or coronary artery bypass grafting; coronary artery disease with stenosis of ≥50% in at least two vessels; previous ischemic stroke, transient ischemic attack, carotid stenosis of at least 50%, or cerebral revascularization; diabetes mellitus; peripheral arterial disease; chronic renal dysfunction, defined as a creatinine clearance of \\\u003C60 ml per minute per 1.73 m2 of body surface area).\n* The patient must be able to give informed consent in accordance with ICH GCP guidelines and local legislation and\u002For regulations.\n\nExclusion Criteria:\n\n* Mechanical or biological heart valve prosthesis;\n* PCI with bare-metal stent insertion;\n* Unsuccessful PCI (\\>30% residual stenosis of the target lesion);\n* Cardiogenic shock during current hospitalization;\n* Adverse bleeding or ischaemic event during current hospitalization;\n* Anaemia (haemoglobin \\\u003C10 g\u002FdL) or thrombocytopenia (platelet count \\\u003C100 x109\u002FL) at screening,\n* Severe renal impairment (creatinine clearance \\\u003C30mL\u002Fmin (estimated CrCl calculated by Cockcroft-Gault equation) at screening;\n* Active liver disease at screening defined as persistently elevated alanine aminotransferase (ALT) or aspartate transaminase (AST) \\>3-fold upper limit of normal (ULN)\n* Use of fibrinolytic agents within 24 hours of screening;\n* Gastrointestinal bleeding within 1 month prior to screening unless, in the opinion of the Investigator, the cause has been permanently eliminated (e.g., by surgery);\n* Major bleeding episode (reduction in the hemoglobin level of at least 2 g\u002FdL, transfusion of at least two units of blood, or symptomatic bleeding in a critical area or organ), including life-threatening bleeding episode (symptomatic intracranial bleeding, bleeding with a decrease in the hemoglobin level of at least 5 g\u002FdL or bleeding requiring transfusion of at least 4 units of blood or inotropic agents or necessitating surgery) within 1 month prior to screening;\n* Stroke within 1 month prior to screening;\n* Major surgery within 1 month prior to screening;\n* Malignancy or radiation therapy within 6 months prior to screening unless, in the opinion of the Investigator, the estimated life expectancy is greater than 36 months;\n* History of intraocular, spinal, retroperitoneal, or traumatic intra-articular bleeding unless the causative factor has been permanently eliminated or repaired;\n* Hemorrhagic disorder or bleeding diathesis (e.g. von Willebrand disease, hemophilia A or B or other hereditary bleeding disorder, history of spontaneous intra-articular bleeding, history of prolonged bleeding after surgery\u002Fintervention);\n* Past an organ transplant or patient on the waiting list for organ transplant;\n* Need for continued treatment with systemic ketoconazole, itraconazole, posaconazole, cyclosporine, tacrolimus, dronedarone, rifampicin, phenytoin, carbamazepine, St. John's Wort or any cytotoxic\u002Fmyelosuppressive therapy.\n* Need for continued treatment with non-steroidal anti-inflammatory drugs (NSAIDs);\n* Pre-menopausal women (last menstruation ≤1 year prior to screening) who: sre pregnant or breastfeeding or are not surgically sterile or are of childbearing potential and not practicing two acceptable methods of birth control, or do not plan to continue practicing an acceptable method of birth control throughout the trial. Acceptable methods of birth control are oral or parenteral (patch, injection, implant) hormonal contraception, which has been used continuously for at least one month prior to the first dose of study medication, intrauterine device or intrauterine system, double-barrier method of contraception (condom and occlusive cap or condom and spermicidal agent), male sterilization and complete sexual abstinence (if acceptable by local authorities). Periodic abstinence is not an acceptable method of contraception.\n* Known allergy to dabigatran, ticagrelor, clopidogrel, aspirin, or to the excipients used for the tables of the drugs;\n* Contraindications, in the Investigator's opinion to dabigatran, ticagrelor, clopidogrel, or aspirin;\n* Participation in another trial with an investigational drug or device within the past 30 days preceding the screening visit (patients participating in an observational study only will not be excluded);\n* Patients who are not willing or able to comply with the protocol requirements or considered unreliable by the Investigator concerning the requirements for follow-up during the study and\u002For compliance with study drug administration, who have a life expectancy less than the expected duration of the trial due to concomitant disease, or who have any condition which in the opinion of the Investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse).","ALL","18 Years",{"count":20,"type":21},1194,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","More than 25% of patients referred for diagnostic coronary angiography and percutaneous coronary intervention (PCI) due to acute coronary syndrome (ACS) suffer from non-valvular atrial fibrillation (AF). In this particular setting, balancing between the prevention of thrombosis and the risk of bleeding remains challenging. Oral anticoagulation (OAC) prevents stroke and systemic embolism, but has not been shown to prevent stent thrombosis (ST). Dual antiplatelet therapy (DAPT) reduces the incidence of recurrent ischemic events and ST, but is less effective in reducing the incidence of cardioembolic stroke associated with AF. A common guideline-supported practice is to combine three drugs (OAC, aspirin and clopidogrel) in a triple therapy, which is associated with high annual risk (up to 25%) of major bleeding. Thus, new therapeutic strategies are urgently needed to maintain the efficacy while improving the safety of treatment in patients with AF and ACS undergoing PCI.\n\nThis is a prospective, randomized, open-label, blinded-endpoint, non-inferiority trial. 1194 patients with non-valvular AF that had undergone successful PCI due to an ACS within the previous 120 hours will be randomized in 1:1 ratio to receive one of the two treatments: dual therapy with dabigatran (150 mg twice daily or 110 mg twice daily) and ticagrelor (90 mg twice daily for 1 month, followed by 60 mg twice daily up to 12 months), or standard therapy according to current guidelines triple therapy with dabigatran (150 mg b.i.d. or 110 mg b.i.d.) plus clopidogrel (75 mg o.d.) plus aspirin (75 mg o.d.) followed by double therapy depending on the bleeding and ischaemic risk. Study treatment will be continued for 12 months. The primary study end-point is the first major or clinically relevant non-major bleeding event (per ISTH), in a time-to-event analysis. The main secondary end-point is a composite efficacy end-point of thromboembolic events (myocardial infarction, stroke, or systemic embolism), death, or unplanned revascularization (PCI or coronary artery bypass grafting) at 12 months.\n\nWe expect that dual antithrombotic therapy including reduced dose ticagrelor and dabigatran is at least non-inferior regarding bleeding risk and ischaemic protection, compared to the standard triple therapy in patients with AF and after ACS, treated with PCI.",[27,28,29,30],"Atrial Fibrillation","Antithrombotic Therapy","Acute Coronary Syndrome","Percutaneous Coronary Interventions",[27,29,32,33,34],"Dabigatran","Ticagrelor","Antithrombotic therapy","RECRUITING","2026-06-14",{"date":38,"type":39},"2026-06-16","ACTUAL",{"date":41,"type":39},"2021-10-25",{"date":43,"type":21},"2026-08-31",{"name":45,"class":46},"Medical University of Gdansk","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":72,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100642101","phase-4-study-of-aspirin-removal-in-patients-supported-by-the-fully-magnetically-levitated-ch-vad-pump-100642101","NCT07644247","STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump","A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump (STAR Trial)","STAR","Inclusion Criteria:\n\n\\-\n\nStudy participants must meet all the following criteria:\n\n1. Age ≥18 years old;\n2. Implanted with the CH-VAD pump for advanced heart failure, and the CH-VAD pump is the first implanted left ventricular assist device;\n3. Able to understand the study purpose, voluntarily participate and sign the informed consent form, and willing to comply with the study procedures and follow-up requirements.\n\nExclusion Criteria:\n\n\\-\n\nStudy participants meet any of the following criteria will be excluded:\n\n1. Requirement for additional temporary or permanent mechanical circulatory support after LVAD implantation;\n2. Requirement for physician-mandated antiplatelet therapy after implantation due to medical history, surgical history, concomitant surgical procedures, or other conditions, including mandated presence or absence of antiplatelet agent;\n3. Occurrence of primary endpoint events prior to randomization (within 2-7 days after implantation);\n4. Inability to take oral medications post-implant through 7 days;\n5. Known allergy to aspirin;\n6. Participation in another clinical investigation that may affect study outcome;\n7. Presence of other comorbid conditions, social or psychological conditions, or other conditions, in the investigator's opinion, that may affect participation in the study or compliance with follow-up requirements.",{"count":57,"type":21},370,[24],"This multi-center, prospective, randomized, double-blinded, placebo-controlled study aims to investigate whether withdrawal of aspirin from the antithrombotic regimen in patients supported with the CH-VAD pump is non-inferior to the standard antithrombotic regimen of vitamin K antagonist combined with aspirin in terms of safety and efficacy.",[61,62,63,64,65,66,67,68,69,70,71,28],"LVAD (Left Ventricular Assist Device) Thrombosis","LVAD","LVAD (Left Ventricular Assist Device)","LVAD-related GI Bleed","Bleeding","Thrombosis","Stroke","Hemocompatibility-related Adverse Event","Ventricular Assist Device","Aspirin","Antiplatelet Therapy",[73,62,67,65,66,74,70,75],"Left ventricular assist device","Hemocompatibility","Antiplatelet","NOT_YET_RECRUITING","2026-06-08",{"date":79,"type":39},"2026-06-12",{"date":81,"type":21},"2026-06-25",{"date":83,"type":21},"2029-12-31",{"name":85,"class":86},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":47},"100427929","protocol-based-management-and-perioperative-outcomes-in-patients-with-chronic-antithrombotic-therapy-100427929","NCT04852406","Protocol-based Management and Perioperative Outcomes in Patients With Chronic Antithrombotic Therapy","Effect of Protocol-based Management on Perioperative Outcomes in Patients With Chronic Antithrombotic Therapy: a Pragmatic Interventional Study","Inclusion Criteria:\n\n* 1\\. Patients with continuing antithrombotic therapy (including antiplatelet and\u002For anticoagulant therapies) for cardiovascular and cerebrovascular diseases for more than 2 weeks.\n* 2\\. Patients who have one or more of the following situations: (1) non-valvular atrial fibrillation with a CHA2DS2-VASc score \\>4; (2) post-artificial valve replacement (including mitral valve, ball-cage valve or tilting disc aortic valve); (3) venous thromboembolism occurred within 1 year, or venous thromboembolism with other high-risk factors which require long-term anticoagulation treatment; (4) coronary heart disease with coronary stent implantation, thrombolytic therapy or other coronary procedures within 2 years, or who had undergone coronary artery bypass grafting within 1 year, or who experienced myocardial infarction or acute coronary syndrome within 1 year; (5) a history of stroke\u002Ftransient ischemic accident within 1 year, or a history of cervical or intracranial revascularization treatment within 1 year; (6) peripheral arterial disease.\n* 3\\. Patients who are scheduled to undergo intra-abdominal surgery (including general and urologic surgery).\n* 4\\. Patients who sign written informed consents.\n\nExclusion Criteria:\n\n* 1\\. Refuse to participate.\n* 2\\. Emergency surgery.\n* 3\\. Unable to complete the preoperative assessment and follow-up plan.\n* 4\\. Other reasons that are considered unsuitable for study participation by the investigators or the attending doctors.",{"count":95,"type":21},526,[97],"NA","The purpose of this pragmatic interventional study is to evaluate whether a protocol-based management of antithrombotic drugs can reduce a composite of perioperative outcomes in patients with chronic antithrombotic therapy before surgery.",[28,100,101],"Perioperative Care","Perioperative Outcomes",[103,104,105],"perioperative care","antithrombotic therapy","perioperative outcomes","2025-07-30",{"date":108,"type":39},"2025-07-31",{"date":110,"type":39},"2021-04-21",{"date":112,"type":21},"2026-01",{"name":114,"class":46},"Peking University First Hospital",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":47},"100599787","endoscopic-evaluation-for-iron-deficiency-anemia-in-patients-on-antithrombotic-therapy-100599787","NCT07089030","Endoscopic Evaluation for Iron Deficiency Anemia in Patients on Antithrombotic Therapy","A Pilot Study Evaluating the Benefit of Endoscopic Assessment for Iron Deficiency Anemia in Patients Receiving Antithrombotic Therapy","BEACON-IDA","Inclusion Criteria:\n\n1. Adult men and postmenopausal women with iron deficiency anemia, and premenopausal women with iron deficiency anemia and a negative gynecological evaluation;\n\n   a. Laboratory-confirmed iron deficiency anemia (hemoglobin \\\u003C 120 g\u002FL for women, \\\u003C 130 g\u002FL for men, and ferritin \\\u003C 30 ng\u002FL);\n2. Patients receiving anticoagulant or antiplatelet therapy\n3. Negative esophagogastroduodenoscopy (EGD), colonoscopy, and capsule endoscopy for gastrointestinal bleeding within six months prior to study enrollment\n4. Willing and able to provide written informed consent\n5. Able to read and understand French\n\nExclusion Criteria:\n\n1. Ongoing overt gastrointestinal bleeding\n2. Acute coronary syndrome, acute neurological event, sepsis, or respiratory failure within the past week\n3. Pregnant women\n4. Known gastrointestinal or hematological malignancy\n5. Contraindications to capsule endoscopy\n6. History of bariatric surgery, gastrectomy, or segmental resection of the small intestine\n7. Inability to take oral iron\n8. Other sources of blood loss (e.g., urinary, gynecological, hematoma, hemolysis)","90 Years",{"count":125,"type":21},20,[97],"This is a single-center, randomized pilot study evaluating the feasibility and safety of two management strategies for patients on antithrombotic therapy who present with obscure gastrointestinal bleeding (OGIB). Participants will be randomized to either repeated endoscopic evaluations or a conservative medical approach with limited testing. The study aims to assess whether conservative management yields similar clinical outcomes and quality of life compared to standard repeated endoscopic procedures. Results will inform the design of a larger trial and address the current lack of guidelines for managing recurrent iron-deficiency anemia in this patient population.",[129,130,28],"Obscure Gastrointestinal Bleeding","Iron-Deficiency Anemia",[129,130,28,132,133,134,135],"Anticoagulants","Antiplatelet Agents","Endoscopy","Gastrointestinal Hemorrhage","2025-07-25",{"date":138,"type":39},"2025-07-28",{"date":140,"type":39},"2023-06-06",{"date":142,"type":21},"2026-06-06",{"name":144,"class":46},"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":47},"100560862","assessing-the-effectiveness-and-safety-of-pericapsular-nerve-group-peng-block-in-hip-fracture-patients-on-antithrombotic-therapy-100560862","NCT06582667","Assessing the Effectiveness and Safety of Pericapsular Nerve Group (PENG) Block in Hip Fracture Patients on Antithrombotic Therapy","Assessing the Effectiveness and Safety of Pericapsular Nerve Group (PENG) Block in Hip Fracture Patients on Antithrombotic Therapy: A Randomized Controlled Trial","PENG Block","Inclusion Criteria:\n\n* Age 65 years or older\n* diagnosis of hip fracture\n* scheduled for surgical intervention within 48 hours\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Allergy to local anesthetics,\n* Contraindications to the PENG block\n* inability to provide informed consent.","65 Years","85 Years",{"count":156,"type":21},100,[97],"PENG block will be done on patients with hip fracture either receiving antithrombotic therapy or not under ultrasound guidance",[160,28,151],"Hip Fracture",[104,162],"PENG block","2024-08-30",{"date":165,"type":39},"2024-09-03",{"date":167,"type":21},"2024-09-17",{"date":169,"type":21},"2025-04-17",{"name":171,"class":46},"Alexandria University"]